TheraRadar
← Back
Data updated: Jun 28, 2026

ABBOTT

Big Pharma
ImmunologyInfectious DiseaseOncology Execution: Excellent

ABBOTT is a major pharmaceutical company focused on Immunology, Infectious Disease, Oncology.

1959
Since
92
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules

ABBOTT at a Glance

  • Strong track record with 88% execution quality across 99 trials
  • Fast trial execution (12 months median completion)

ABBOTT's Key Drugs

ABBOTT's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

ABBOTT's Recent FDA Approvals

New NDA/BLA approvals for ABBOTT over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ABBOTT's Therapeutic Areas

ABBOTT's approved drugs and pipeline span 5 therapeutic areas, led by Immunology and Infectious Disease, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 31%
0 drugs Phase 3: 20 Phase 2: 7 Phase 1: 11
Infectious Disease 25%
2 drugs Phase 3: 8 Phase 2: 15 Phase 1: 13
Oncology 17%
0 drugs Phase 3: 2 Phase 2: 11 Phase 1: 30
Neurology 14%
1 drugs Phase 3: 5 Phase 2: 10 Phase 1: 2
Metabolic 13%
1 drugs Phase 3: 5 Phase 2: 6 Phase 1: 6

ABBOTT Pipeline Snapshot

ABBOTT has 151 active clinical programs from ClinicalTrials.gov — 40 Phase 3, 49 Phase 2 and 62 Phase 1.

40
Phase 3
49
Phase 2
62
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Immunology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 28/31 completed
  • • Speed: 12 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges